Acro Biomedical Q2 2026: Going Concern Doubts Intensify as Cash Dwindles to $3,648
ACBM filed a Earnings and Guidance on light trading volume (0.1× avg).
Summary
Acro Biomedical reported a net loss of $65,130 for the first half of 2026, with cash of only $3,648 and a working capital deficiency of $444,789. The company continues to face substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · ACBM
-
Going Concern Warning Reiterated
The company states substantial doubt about its ability to continue as a going concern within one year, citing no revenue since December 31, 2022, minimal cash, and negative cash flow from operations.
-
Net Loss Widens
Net loss for the six months ended June 30, 2026 was $65,130, up from $25,863 in the prior year period, driven by higher operating expenses and related-party interest.
-
Cash Position Deteriorates
Cash decreased to $3,648 at June 30, 2026 from $4,098 at December 31, 2025, while working capital deficiency increased to $444,789 from $386,964.
-
Reliance on Related Party Advances
The company received $59,875 in advances from a minority stockholder during the six months ended June 30, 2026, its primary source of funding.
Analysis · ACBM · Trade & Services
Acro Biomedical's Q2 2026 report shows a company with no revenue, minimal cash, and a growing working capital deficiency. The going concern warning is reiterated, and the company relies entirely on advances from a minority stockholder to stay afloat. The lack of an active trading market for its stock makes raising capital difficult, increasing the risk of insolvency.
At the time of this filing, ACBM was trading at $0.03 on OTC in the Trade & Services sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.00 to $9.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.